Top trend #4: We’re com­ing to a tip­ping point on can­cer R&D, and it may not be pret­ty

Can­cer of the right kid­ney, seen on a cross-sec­tion ab­dom­i­nal scan BSIP/UIG, Get­ty

The big trend for the past 5 years in bio­phar­ma R&D has clear­ly fo­cused on new can­cer ther­a­pies. The whole in­vest­ment scene has tilt­ed to­ward on­col­o­gy with a vengeance, pour­ing bil­lions in­to all and any new can­cer ther­a­pies that look like they can make a dif­fer­ence — or could if they were paired up with a check­point ther­a­py.

My bet is that we’re near­ing a tip­ping point, where the prospect of di­min­ish­ing re­turns be­gins to re­store some sem­blance of bal­ance in the way cash is in­vest­ed in biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER